Privia Health Group, Inc. revised earnings guidance for the year 2023. For the year, the company expects revised GAAP revenue of Mid to High End compared to previously expected GAAP revenue to be in the range of $1,550 million to $1,650 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.99 USD | +0.11% | -5.71% | -21.88% |
05-10 | UBS Adjusts Privia Health Group Price Target to $26.50 From $29, Maintains Buy Rating | MT |
05-09 | Transcript : Privia Health Group, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.88% | 2.14B | |
+17.18% | 85.55B | |
-28.48% | 70.07B | |
+6.76% | 28.95B | |
-7.44% | 17.51B | |
+2.14% | 17.39B | |
+2.10% | 15.38B | |
+7.02% | 13.4B | |
+64.96% | 12.93B | |
+6.64% | 12.77B |
- Stock Market
- Equities
- PRVA Stock
- News Privia Health Group, Inc.
- Privia Health Group, Inc. Revises Earnings Guidance for the Year 2023